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Abstract: Estradiol exerts neuroprotective actions that are mediated by the regulation of a variety of
signaling pathways and homeostatic molecules. Among these is neuroglobin, which is upregulated
by estradiol and translocated to the mitochondria to sustain neuronal and glial cell adaptation to
injury. In this paper, we will discuss the role of neuroglobin in the neuroprotective mechanisms
elicited by estradiol acting on neurons, astrocytes and microglia. We will also consider the role of
neuroglobin in the neuroprotective actions of clinically relevant synthetic steroids, such as tibolone.
Finally, the possible contribution of the estrogenic regulation of neuroglobin to the generation of
sex differences in brain pathology and the potential application of neuroglobin as therapy against
neurological diseases will be examined.
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1. Introduction
The central nervous system (CNS) is a target for the ovarian hormone estradiol, which
not only regulates the activity of the neuronal circuits controlling reproductive physiology,
sexual behavior and energy homeostasis, but also of those participating in the processing of
tactile, nociceptive, visual and auditory information, motor coordination, emotions, verbal
skills, cognition, learning and memory. Estradiol also activates protective homoeostatic
responses in neurons, astrocytes, microglia, oligodendrocytes and endothelial cells to
maintain the function of all of these circuits under pathological conditions.
After CNS injury, the hormone reduces edema, oxidative stress, neuroinflammation,
altered ionic balance, apoptosis, loss of cerebral blood flow and other tissue alterations that
cause secondary neuronal death and contribute to expanding the damage over other CNS
regions. In parallel, estradiol activates reparative mechanisms through the regulation of
autophagy and the promotion of synaptic plasticity, postnatal neurogenesis and myelin re-
pair [1]. In consequence, estradiol is neuroprotective in animal models of depression, stroke,
traumatic CNS injury, multiple sclerosis, amyotrophic lateral sclerosis, Parkinson’s disease,
diabetic and hypertensive encephalopathies, Alzheimer’s disease and other illnesses of the
nervous system [1–6].
Both under physiological conditions and after CNS injury, estradiol regulates neuronal
and glial cell function by a coordinated activation of extranuclear and nuclear signaling
events [1]. Nuclear-initiated estrogen signaling is mediated by classical estrogen receptors
(ERs), α (ERα) and β (ERβ), which are transcription factors expressed by neurons, astro-
cytes and microglia [7,8] and are widely distributed in numerous brain regions, including
those that are frequently involved in neurodegenerative diseases, such as the hippocampus,
cerebral cortex and the striatum [7,8]. These receptors can be coexpressed in the same
individual brain cells [7] and, after being activated by the hormone, form homo or het-
erodimers, recruit coactivators, corepressors and other components of the transcriptional
machinery and regulate transcription by binding to estrogen response elements in the
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promoters of target genes, or by interacting with other transcription factors in the cell
nucleus [9].
Extranuclear-initiated estrogen signaling is mediated by classical ERs localized at
extranuclear sites, such as at lipid rafts of the plasma membrane [10] or at the mitochon-
dria [11], or by activating other types of ERs, such as G protein-coupled estrogen receptor-1
or Gq-coupled membrane estrogen receptor at the plasma membrane or the endoplasmic
reticulum [12,13]. Extranuclear estrogen signaling results in the modification of the activity
of ion channels, kinases, phosphatases and the signaling pathways of membrane-associated
receptors, such as insulin-like growth factor-1 (IGF-1), Wnt and Notch signaling [1,12–14].
All these signaling pathways modulated by estradiol converge in the regulation of tran-
scriptional events that are in turn coordinated with the transcriptional regulation activated
by nuclear estrogen signaling [15]. Under conditions of brain injury, the activation of
these nuclear and extranuclear initiated signaling mechanisms mediate the neuroprotective
actions of estradiol.
The neuroprotective actions of estradiol are in part exerted through the transcriptional
upregulation of neurotrophic factors and other protective molecules [1,14]. One such
molecule is neuroglobin (Ngb) [16], a globin protein family member that is expressed by
neurons and glial cells in the mammalian central and peripheral nervous system [17,18] and
exerts neuroprotection [19,20]. Here we will review the protective actions of neuroglobin
over glial and neuronal cells, focusing especially on the neuroglobin-enhancing actions of
hormonal compounds as a therapeutic strategy to alleviate brain damage.
2. Neuroglobin Neuroprotective Actions
In neural cells, neuroglobin interacts with proteins involved in signal transduction [16]
and regulates the activity of different signaling pathways, including PI3K [21], AMP-
activated protein kinase (AMPK) [22] and Wnt signaling [23]. In addition, neuroglobin
regulates mitochondrial dynamics [19], mitochondrial respiratory function and ATP pro-
duction [24,25] and regulates cell metabolism [22]. However, the physiological conse-
quences of all these effects of neuroglobin in the mammalian brain have been only partially
explored. Nevertheless, it is known that neuroglobin promotes neurogenesis, possibly
by increasing PSA-NCAM, Tuj1 and involving Wnt signaling [23,25,26] and neuritogene-
sis [27,28].
In aquatic mammals, such as whales and seals, neuroglobin is involved in the physio-
logical adaptation to hypoxia when submerged [29], suggesting that in terrestrial mammals,
neuroglobin may participate in the adaptation to brain hypoxia under pathological condi-
tions. In agreement with this possibility, it was shown that neuroglobin protects neural
cells against hypoxia-ischemia [24,30,31], oxidative stress [32] and oxygen/glucose de-
privation [33] and reduces infarct lesion after experimental stroke [34–36]. Moreover,
the fact that vascular endothelial growth factor (VEGF) stimulates neuroglobin through
VEGFR2/Flk1 [37] may also suggest the involvement of neuroglobin in neovascularization
and angiogenesis, two essential repairing cellular mechanisms that are severely disturbed
in cerebral ischemia.
The investigation of the possible protective actions of neuroglobin and its molecular
mechanisms has been addressed using a variety of cellular and animal models [38]. These
studies have revealed that the neuroprotective actions of neuroglobin are not limited to
hypoxic-ischemic insults. For instance, overexpression of neuroglobin in transgenic mice
using adenoviral vectors reduces lesion size [39] and improves sensorimotor behavior [40]
after traumatic brain injury (TBI) and promotes locomotor recovery after spinal cord in-
jury [41]. In addition, neuroglobin overexpression protects neuronal cells from NMDA [42]
and β-amyloid toxicity [42–44] and decreases behavioral deficits in mice with Alzheimer’s
disease [40]. On the other hand, the expression of neuroglobin declines in the brain in
Huntington’s disease mouse model and in Alzheimer’s disease patients in parallel to the
increase in pathological alterations [45,46].
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Mitochondria have emerged as a central component in the neuroprotective actions
of neuroglobin [19,20]. Indeed, neuroglobin is physically localized in neuronal mitochon-
dria [47] and its overexpression in primary neurons exposed to hypoxia results in the
preservation of mitochondrial membrane potential and respiration, the enhancement of
ATP production and reduced oxidative stress [48]. In addition, neuroglobin interacts with
several mitochondrial proteins involved in the regulation of the intrinsic pathway of apop-
tosis, such as cytochrome-c1, voltage-dependent anion channel 1 (VDAC) or huntingtin
(HTT) [16,49–51] and protects neuronal cells by inhibiting this cell death pathway [52].
The neuroprotective mechanisms of neuroglobin also include actions outside the
mitochondria. For instance, oxidative stress promotes the recruitment of neuroglobin
into lipid raft microdomains of the plasma membrane. There, neuroglobin interacts with
flotillin-1 and α-subunits of heterotrimeric G proteins, preventing the decrease in cAMP
levels induced by oxidative stress and promoting neuronal viability [32]. Neuroglobin
also preserves the activity of Na+/K+ ATPases in the membrane, as it has been detected in
the hippocampus in a model of transient global cerebral ischemia [53]. Na+/K+ ATPases
are essential to maintain intracellular ion homeostasis and membrane excitability. Indeed,
the preservation of its activity by neuroglobin after transient global cerebral ischemia is
associated with reduced damage to CA1 hippocampal neurons [53]. Another localization
of neuroglobin are the neuronal growth cones [54], structures involved in axonal growth
and axonal regeneration. Indeed, neuroglobin has been shown to promote the regeneration
of CNS axons after traumatic injury or ischemia [54,55].
The preservation of the activity of Na+/K+ ATPases by neuroglobin is associated
with an increased membranous level of Na+/K+ ATPases β1 subunit in astrocytes [53],
suggesting a role of these glial cells in the mechanisms of neuroprotection. This is in
agreement with the fact that neuroglobin expression is enhanced in astrocytes and microglia
after brain injury [53,56–59]. Furthermore, it has been shown that exogenous intravitreal
injection of neuroglobin reduces the activation of microglia, the expression of inflammatory
cytokines and the apoptosis of retinal ganglion cells in hypoxic retina [60]. Therefore,
the control of neuroinflammation by astrocytes and microglia may participate in the
neuroprotective response mediated by neuroglobin.
Astrocytes not only mediate neuroglobin neuroprotection, but they are also protected
themselves by neuroglobin. Thus, neuroglobin increases the viability of astrocytes exposed
to glucose deprivation or oxidative stress [61–63]. To better understand the importance of
neuroglobin for cell survival, neuroglobin-depleted astrocytes lose mitochondrial mem-
brane potential (∆Ψm), alongside increases in superoxide (O−2) and hydrogen peroxide
levels (H2O2), while attenuating the levels of two antioxidant enzymes: catalase and su-
peroxide dismutase 2 (SOD2, mitochondrial) [64,65]. This may be indicative of loss of
mitochondria integrity and function, thereby promoting cell death. In agreement with this,
when knocking down neuroglobin, pAKT/AKT is downregulated in an in vitro scratch
and metabolic injury model, therefore worsening cell viability [65]. Given the essential
trophic and metabolic support provided by astrocytes to neurons, it should be expected
that the protection exerted by neuroglobin on astrocytes should also contribute to sus-
tain neuronal viability. In this regard, it is noticeable that neuroglobin is transported in
exosomes from astrocytes to neurons [66], a mechanism that may help to coordinate the
protective responses in both cell types.
Despite the benefits of neuroglobin over neuronal and glial cells post-injury, its clinical
use is hampered because it is unable to cross membranes, or even penetrate through
the blood–brain barrier (BBB), due to its physical properties and hydrophilic exterior.
To circumvent this problem, transactivator of transcription protein (TAT) has been used
to deliver neuroglobin to the brain. Indeed, rabbits treated with neuroglobin coupled
with TAT transduction domain (TAT-Ngb) had improved neuronal outcome in terms of a
significant reduction in apoptotic mechanisms in a model of subarachnoid hemorrhage [67].
Furthermore, TAT-Ngb fusion proteins preserved mitochondrial function upon oxidative
damage by inducing a significant rise in superoxide dismutase, heme-oxygenase 1 (HO-1)
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and nuclear factor erythroid 2-related factor 2 (Nrf2) [68]. However, some challenges have
been mentioned in the attempts made to facilitate neuroglobin delivery to the brain. For
example, TAT-Ngb-FITC has been shown to penetrate cortical neurons in vitro, but a caveat
of its therapeutic efficacy was the absence of fluorescent signals after 48 h [69]. This is
a major downside when considering times post-injury, a critical period in neurological
diseases as traumatic brain injury. Furthermore, SH-SY5Y (dopaminergic neurons) pre-
treated with TAT-Ngb (400 nM–1 µM) 2 h prior to oxygen glucose deprivation (OGD) for
18 or 36 h had no improvements on cell viability [70]. On the contrary, TAT-Ngb rescued
differentiated PC12 cells from OGD and inhibited mitochondrial apoptosis, possibly by
modulating the Jak stat family [71]. In accordance with this in vitro study, administration
of TAT-Ngb to mice 2 h prior to middle cerebral artery occlusion (MCAO) reduced infarct
volume at 24 h reperfusion and decreased neuronal death by 72 h after MCAO [35].
Although promising, most studies using neuroglobin delivery approaches have been
performed on brain ischemia in vivo and in vitro models, demonstrating the urgent need
to implement these approaches for other brain diseases. More recently, the use of sodium
hyaluronate to facilitate the delivery of neuroglobin following MCAO and 24 h reperfusion
has been explored [72]. Although this nanocarrier successfully delivered neuroglobin to
the brain, the potential biological implication of the rise of its cytosolic levels was not
fully explored.
3. Interaction of Estradiol and Neuroglobin Neuroprotective Actions
The neuroprotective actions of estradiol and neuroglobin share several common mech-
anisms. In part, this is due to the fact that the neuroglobin gene is upregulated by estradiol
in neurons [73] and glial cells [57]. The regulation of neuroglobin expression by estra-
diol is exerted through membrane-initiated estrogen signaling, involving ERβ activation
of p38/MAPK [73], and also by direct nuclear-initiated transcriptional regulation of the
neuroglobin gene by ERα and ERβ, which probably act by binding to other transcription
factors, such as Sp1, activator protein 1 (AP-1) or NF-κB, given the absence of canonical
estrogen response elements the neuroglobin promoter [73–76].
It is possible that the mechanisms of neuroglobin regulation by estradiol may differ
between different cell types and depending on the physiological conditions. For instance,
in astrocytes, the regulation of neuroglobin expression is modified by inflammatory signals.
Thus, under basal conditions the induction of neuroglobin expression by estradiol in
astrocytes is mainly regulated through ERβ. However, a synergic action of ERα and ERβ,
which are coexpressed in astrocytes, is necessary to maintain the neuroglobin expression
upregulated when NF-κB is activated by lipopolysaccharide (LPS) in these cells [57].
Another factor involved in the estrogenic regulation of neuroglobin is huntingtin (HTT),
because in the mouse hippocampus and in murine striatal neurons the polyQ mutation of
HTT causes the disease and impairs the upregulation of neuroglobin by estradiol [51].
In addition to increasing neuroglobin expression, estradiol promotes the accumulation
of neuroglobin in the mitochondria in neuronal cells [50]. HTT is also necessary for
this hormonal effect [51]. Indeed, estradiol promotes the expression of HTT and the
formation of an HTT-neuroglobin complex and its translocation to the mitochondria [51].
In the mitochondria, HTT [77] and neuroglobin [49] interact with proteins involved in the
control of apoptosis, such as VDAC. Through VDAC, neuroglobin inhibits the opening
of mitochondrial permeability transition pore (mPTP) and the subsequent cytochrome
c release [33]. Interestingly, estradiol also promotes the association of neuroglobin with
cytochrome c [50]. This effect of estradiol is enhanced under conditions of oxidative stress
and is one of the mechanisms activated by the hormone to prevent apoptosis. Thus, in
neuroblastoma cells exposed to H2O2, the hormone further increases the mitochondrial
association of neuroglobin with cytochrome c, preventing its release from the mitochondria
to the cytosol and, therefore, the initiation of the apoptotic cascade [50].
Neuroglobin may also be involved in the neuroprotective actions of estradiol mediated
by glial cells. Indeed, part of the neuroprotective actions of estradiol are mediated by the
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control of reactive gliosis and the reduction of the inflammatory response of astrocytes and
microglia [78,79].
Neuroinflammatory response requires complex homeostatic regulation, because from
one side neuroinflammation is an acute protective response but it may enhance neuronal
damage when it is decontrolled as, for instance, under chronic neurodegenerative condi-
tions. The regulation of neuroglobin expression in astrocytes is a good example of this
complex homeostatic regulation. Thus, from one side inflammatory signaling through
NF-κB, and estradiol signaling through ERβ, promote neuroglobin expression in astrocytes,
probably as a protective response [57]. However, in parallel, estradiol inhibits NF-κB
activation and the inflammatory response of astrocytes by a mechanism involving ERα,
and, in doing so, the hormone also reduces NF-κB-mediated induction of neuroglobin [57].
These opposite actions of estradiol may be interpreted as a mechanism to maintain the
level of the inflammatory response under an adequate control.
4. Potential Role of Neuroglobin in the Generation of Sex Differences in
Brain Pathology
The estrogenic actions in the nervous system contribute to sex differences in the
incidence, prevalence, age of onset or symptomatology that are observed in numerous
neurodegenerative and affective disorders [8], including pathological conditions in which
neuroglobin has been reported to exert neuroprotective actions in animal models. It is
plausible that a sex-specific regulation of neuroglobin expression in neurons and glial cells
by circulating estradiol, or by estradiol locally synthesized by brain aromatase enzyme [80],
may contribute to the generation of these differences. However, this possibility has not
received enough attention in the experimental designs, which usually utilize only one
animal sex. Nevertheless, it has been reported that female mice have higher basal levels
of neuroglobin in the hippocampus [51] and the striatum [46] than males. However, it is
still unknown if these differences offer a better protection of the female hippocampus and
striatum against pathological insults.
Sex differences in the expression of neuroglobin after brain injury have also been
scarcely explored, although a significant increase in neuroglobin expression has been
observed in the striatum of transgenic male mice affected by Huntington’s disease, but
not in female animals affected by the pathology [46]. In contrast, neuroglobin mRNA
levels increase in the cerebral cortex of female rats, but not in the male cortex, after
ischemic stroke [81]. Since there is a significant negative correlation between the expression
of neuroglobin and the volume of cortical infarct [81], sex differences in neuroglobin
expression after brain injury may be potentially involved in the decreased brain infarct
volume observed in young female animals in the acute phase of ischemic stroke [82].
Sex differences have also been observed in the cellular localization of neuroglobin
in a mouse model of a penetrating traumatic brain injury. In this model, neuroglobin
expression in the injured cerebral cortex was restricted to the tissue located in proximity
to the wound and was detected in neurons, reactive astrocytes and microglia [57,59]. The
area of neuroglobin expression near the wound on day 7 post-injury was similar in 2-
month-old males and females. However, the cellular distribution of neuroglobin was
different, with males presenting a higher colocalization of neuroglobin with the microglia
marker ionized calcium binding adaptor molecule 1 (Iba1) than females [59]. A similar
outcome was also observed in 5-month-old male animals under a controlled cortical impact
model showing an upregulation of neuroglobin in the ipsilateral hemisphere by day 7 after
injury [40]. Interestingly, a positive correlation seems to exist between the severity of the
damage and the degree of neuroglobin expression in males [83]. However, the pattern of
neuroglobin expression over post-TBI periods might depend on the time of assessment.
Thus, a thorough evaluation of spatiotemporal neuroglobin levels is utterly necessary for a
precise time course of its evolution during acute and chronic TBI periods.
The consequences of these differences in neuroglobin cellular distribution for the
functional response of the cerebral cortex to injury are still unknown. Although males show
a higher neuronal survival in the lesion border of the cerebral cortex than females [59], this
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could not be ascribed to the differences in neuroglobin localization in microglia. However,
this question merits further investigation, considering that neuroglobin expression in
microglia is observed after different forms of cellular injury [58,84,85] and that these cells
react to pathological insults with sex-specific inflammatory, migratory and phagocytic
responses [8].
5. Role of Neuroglobin in the Neuroprotective Actions of Natural and Synthetic
Compounds with Estrogenic Activity
Health benefits have been associated with the use of several natural compounds with
estrogenic activity, such as the isoflavone genistein, which is known to exert neuropro-
tective actions in animal models of neurodegeneration [86–88]. It has been reported that
genistein—and another isoflavone, formononetin—increases neuroglobin expression in
primary neurons [89], suggesting that neuroglobin may participate in the neuroprotec-
tive actions of phytoestrogens and that these molecules may be used as pharmacological
inductors of neuroglobin.
Synthetic steroids with estrogenic activity have also been shown to induce neuroglobin
expression in neural cells. Thus, it has been reported that the synthetic steroid diarylpro-
pionitrile (DPN), a selective agonist of ERβ that exerts neuroprotective actions [90–92],
induces the expression of neuroglobin in SK-N-BE neuroblastoma cells, while propyl
pyrazole triol (PTT), a selective agonist of ERα, does not [73].
Another synthetic steroid with estrogenic actions that has been shown to upregulate
neuroglobin in neural cells is tibolone. Tibolone is a selective tissue estrogenic activity
regulator currently used in clinical practice for the treatment of osteoporosis and climacteric
symptoms. Following administration, tibolone is converted into 3α-hydroxytibolone, 3β-
hydroxytibolone and δ4-tibolone [93–96]. These metabolites are highly lipophilic, able to
cross plasma membranes, hence penetrating the BBB, and act as agonists of androgen (AR),
ERs and progesterone (PGR) receptors. Thus, 3α and 3β metabolites preferentially bind
to ERs, mainly ERα, while δ4-tibolone binds to AR and PGR [97]. In the nervous system,
tibolone exerts neuroprotective actions and promotes cognition [98,99], probably by acting
in part over glial cells through the attenuation of the reactive activation of astrocytes and
microglia after traumatic brain injury [100], and the regulation of astrocyte phagocytosis of
brain cellular debris [101].
The induction of neuroglobin signaling is one of the neuroprotective mechanisms acti-
vated by tibolone (Figure 1). Upon binding to tibolone metabolites (α, β, and δ), ER, ARs
and PGR are activated, migrate to the nucleus and interact with steroid hormone response
elements localized in the promotor or upstream of Ngb gene. Although this genomic mech-
anism may stimulate the expression of neuroglobin in both glial cells and neurons, this
protein can also be regulated by non-genomic signaling through activation of PI3k/AKT
and p38/MAPK. Once activated, neuroglobin may interact with G protein alpha subunit
(Gα) and phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase (PTEN) leading to the
activation of survival signaling in neurons and glial cells. Estrogenic signaling not only in-
creases neuroglobin expression, but also induces its translocation to the mitochondria [50].
Then, neuroglobin interacts in the mitochondria with cytochrome c, mitochondrial complex
proteins and scavenge ROS and NOS. Collectively, these actions carried out by neuroglobin
indicate its antioxidative, anti-inflammatory, and antiapoptotic properties in the brain.
Finally, by regulating these pathways, tibolone reduces the inflammatory response and
increases the viability of microglia cells exposed to a metabolic insult by a mechanism
involving ERβ activation, NF-κB inhibition and neuroglobin upregulation [85]. A similar
mechanism, involving mainly ERβ, but also ERαmediated neuroglobin upregulation, is
activated by tibolone to protect astrocytes from glucose deprivation [62]. The neuroprotec-
tive actions of tibolone are of interest, given that this compound is currently used in clinical
practice. However, systemic off-target effects of tibolone may limit its use as a treatment
for specific brain diseases.
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Figure 1. Transcriptional and post-translational regulation of neuroglobin (NGB) and biological
functions. Abbreviations: T, tibolone; α, 3α-hydroxytibolone; β, 3β-hydroxytibolone; δ, δ4-tibolone;
AR, androgen receptor; ERα, estrogen receptor alpha; ERβ, estrogen receptor beta; PGR, progesterone
receptor; cytc, cytochrome c; βγ, G protein beta and gamma subunits; PTEN, phosphatidylinositol
3,4,5-trisphosphate 3-phosphatase; ROS, reactive oxygen species; RNS, reactive nitrogen species.
6. Conclusions and Perspectives
Since its discovery and until the present day, neuroglobin has shown enormous poten-
tial as a therapy against inflammation and oxidative stress due to its common pathological
features across many neurological diseases, including stroke, Alzheimer’s disease and trau-
matic brain injury, among others. The fact that in some CNS diseases, such as Alzheimer’s,
the intracellular levels of neuroglobin decrease exponentially with time of injury suggests
the intrinsic participation of this protein in the pathological mechanism. It should be
noted that the expression of neuroglobin and its downstream signaling might be different
depending on the sex, and therefore further studies exploring the sex dimorphic role of
neuroglobin is expected.
Perhaps one of the greatest current challenges is to seek strategies that aim to increase
both the levels and the cellular expression of neuroglobin. One strategy that has been
explored in the last few years is the delivery of neuroglobin to increase its brain levels, espe-
cially in those diseases characterized by a significant reduction of endogenous neuroglobin.
Considering the inability of this protein to cross membranes after brain delivery, it seems
that the effect is transient and limited as its intracellular levels do not remain for a long
time inside cells post-injury. Even if deliv ry is successful and steady, further studies are
n eded to delve into whether a rise in neuroglobin is d rect y correlated with an increased
neurop o ect on, so future work to u ravel this possible relati nship is warranted.
Fi ally, ndogenously, n ur globin can be stimulated by genomic and nongenomic
pathways, where a wide range of pharmacological compounds have the ability to promote
its expression. One of these groups capable of stimulating the transcriptional activity of
Ngb gene in neurons and glial cells are compounds with estrogenic activity, which can be
those of endogenous origin such as estradiol or of synthetic origin such as tibolone. In
both cases, brain cells treated with these estrogenic compounds have a better outcome
against an inflammatory stimulus, possibly by activating the endogenous synthesis of
neuroglobin and ERs, since the blockade of the estrogen receptors (i.e., ERβ) is able to
reduce the protection mediated by this protein. A limiting factor for a long-term therapy
with estrogenic compounds is related to the side effects that can occur in other peripheral
organs. Therefore, the discovery and design of more specific ligands using high-throughput
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screening and artificial intelligence/machine learning [102] targeting estrogen receptors
only in the brain is desirable with further studies going forward in this direction.
In conclusion, regardless of the approach that may favor and stimulate neuroglobin,
the neuroprotective potential of this protein is yet far from being fully explored in males
and females. Unravelling which other biological functions this protein has in the brain
upon injury merits to be the subject of future studies.
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